Cipla
Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M.
Cipla vs Emcure Pharmaceuticals Q4 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Emcure Pharmaceuticals
Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 crore (+16.7% YoY) and EBITDA margin expansion of 130 bps to 19.7%, driven by robust international growth (+25.7%) and operating leverage.
Result Snapshot
Revenue₹6,541 Cr₹2,470 Cr
PAT₹543 Cr₹244 Cr
EBITDA Margin15%19.7%
Sentimentbullishbullish
Key Quotes
We are expecting to launch this product within the coming months. Our Goa facility together with two US facilities is well equipped to support the launch of all four respiratory assets planned for FI27.
We crossed a major milestone this year, surpassing $1 billion in revenue and having a growth of 16.6% year-on-year increase, exceeding the guidance row that we had given to you.